
Pharmaceutical firm Lundbeck is hoping to avoid the costly blunders of the past, and has therefore halted one of its drug hopes meant to treat the feared brain condition known as Alzheimer’s disease. At least for the time being.
”We’ve parked Lu AF97908 because we don’t have a single piece of evidence in the world that such an antibody works,” says Johan Luthman, head of research and development at Lundbeck.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app